

ILD 진단하기 – 임상적 접근

JUNE. 25. 2022

Jin Woo Song


Univ. of Ulsan College of Medicine

Asan Medical Center


Interstitial Lung Disease

- Diverse group of disorders that involve the distal pulmonary parenchyma
- Patients typically presented with
 - Progressive dyspnea and cough
 - Abnormal pulmonary physiology
 - Abnormal CXR and/or HRCT
- Idiopathic or associated with systemic diseases (CTDs) or environmental exposures


- UIP pattern




- NSIP pattern




- OP pattern




- DIP pattern




- RB pattern




- LIP pattern



- DAD pattern




Splitting in ILD: classification




*Not an established clinical diagnosis.

Survival difference according to ILD subtypes


- Korean IIP registry



- Indian ILD registry



Management of fibrosing-ILD




Steroid – harmful

May stable patients

CTD, connective-tissue disease; c/w, consistent with; HP, hypersensitivity pneumonitis; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; MDD, multidisciplinary discussion; PFTs, pulmonary function tests; UIP, usual interstitial pneumonia


Higher mortality is associated with delays in accessing care

- Survival from the time of evaluation (adjusted for age, sex and FVC)



- Prospective IPF cohort (n=129); median delay from the onset of dyspnea to the date of initial evaluation: 2.2 years (IQR .0-3.8 years)

Algorithm for the diagnosis of ILD




ILD: clinical manifestations

Similarities	Differences
<ul style="list-style-type: none">• Dyspnea<ul style="list-style-type: none">— Progressive— Exertional• Cough<ul style="list-style-type: none">— Non-productive• Bibasilar crackles• Finger clubbing• Restrictive ventilatory defect• Exertional desaturation	<ul style="list-style-type: none">• Demographics• Duration of symptoms• Prior/current exposures • Extrapulmonary findings<ul style="list-style-type: none">— Sarcoidosis— Connective tissue disease— Joint involvement• Serologies

IPF: prevalence by age and sex stratification

Old people's disease



- Men > women
- > 50 years of age
- Average age of diagnosis: 66 years

Differences : IPF vs. other ILDs


	IPF	fHP	fNSIP	SJS-IP	RA-IP	COP
Patient Number	1114	101	72	62	310	76
Age	65.7(8.2)	60.4(12.8)	54.3(10.1)	59.8(11.4)	61.7(10.3)	56.0(11.5)
Male	897(80.5)	50(49.5)	23(31.9)	10(16.1)	137(44.2)	31(40.8)
Ever-smokers	846(75.9)	38(37.6)	21(29.2)	14(22.6)	139(44.8)	21(26.7)

Onset of disease: subacute, acute


- COP



- AIP




- AE of IPF




Exposure: smoking


- DIP




- RB-ILD



- PLCH



- IPF, RA-ILD




Known causes of ILD

- Occupational/Environmental
 - Inorganic antigens (Pneumoconioses)
 - Asbestosis
 - Coal worker's pneumoconiosis
 - Silicosis
 - Organic antigens (Hypersensitivity Pneumonitis)
 - Birds
 - Mold
 - www.hplung.com
- Drugs
 - eg, Amiodarone, bleomycin, nitrofurantoin
 - www.pneumotox.com
- Radiation
 - External beam radiation therapy to thorax
- Connective Tissue Diseases
 - Rheumatoid arthritis
 - Systemic sclerosis (scleroderma)
 - Idiopathic inflammatory myopathies
 - Vasculitis

Pneumoconiosis

- Silicosis, Coal worker's pneumoconiosis
- Asbestosis






Exposure: Silica



Exposure: Asbestos



Pathogenesis of HP



Sources of antigens known to cause HP

Matter	Matter	Typical Sources	HP "Disease"
Organic particulate matter	II. Pharmaceutical agents		
I. Microbes	Penicillins, cephalosporins	Antibiotics	Drug-induced HP
Fungi/molds	Methotrexate	Immunosuppressive agents	
<i>Aspergillus</i> spp.	α -IFN	Immunomodulatory agents	
<i>Alternaria alternata</i> , <i>Aureobasidium</i> spp.	Lenalidomide	Hypolipidemics	
<i>Botrytis cinerea</i>	Pravastatin	Antidepressants	
<i>Cephalosporium</i> spp.	Venlafaxine	Alkylating agents	
<i>Cladosporium</i> spp.	Temozolomide		
<i>Cryptococcus</i> spp.	III. Metals		
<i>Fusarium</i> spp.	Cobalt	Hard metals, alloys	Giant cell pneumonitis
<i>Graphium</i> spp.	Zinc (tungsten and alloys)	Zinc fumes	Zinc-fumes alveolitis
<i>Mucor</i> spp.	Zirconium	Zircon	Zirconium alveolitis
<i>Penicillium</i> spp.	Beryllium	Batteries, computers, neons	Beryllium HP
<i>Rhizopus</i> spp.	TMI	Organometallic compound for semiconductors used in industry	—
<i>Trichoderma</i> spp.			
Phytase (enzyme from <i>Aspergillus</i> <i>Trichoderma</i>)	Shell protein (oyster, sea snail, mussels)	Oyster-shell powder	Shellfish alveolitis, oyster-shell HP, mollusk-shell HP
	Pig pancreas	Animal extracts	—
	Pituitary proteins	Pituitary powder	Pituitary snuff-taker's lung
	Rat and desert mouse (gerbil) urine, serum, pelts	Rats, gerbils	Alveolitis due to rat and mouse proteins
	Silkworm proteins	Dust from silkworm larvae and cocoon	Silkworm rearer's lung
	Weevils (corn, wheat) (<i>Sitophilus</i> spp.)	Contaminated grain or flour	Corn (wheat)-weevil lung
Yeasts	Plant proteins		
<i>Candida</i> spp.	Alginate	Seaweed	—
<i>Geotrichum candidum</i>	Argan cake	Cosmetics, unsaturated fatty acids, phytosterol	—
<i>Saccharomyces cerevisiae</i>	Catechin	Green-tea powder	—
<i>Saccharomonospora viridis</i>	Esparto dust	Esparto grass	Esparto lung, plasterer's lung
<i>Saccharopolyspora rectivirgula</i>			

Exposure: HP

- Farmer's lung (Aspergillus sp.)



- Hot-tub lung (NTM)



- Bird-breeder's lung, Feather-duvet lung (Avian droppings, serum, feathers)



Exposure: HP

- Mouldy walls, Steam iron alveolitis (Iron's steam), Humidifier lung (Alternaria alternate, Candida)



- Saxophone player's lung (Ulocladium botrytis, Penicilium), Trombone player's lung



HP: exposure history to causative antigens

Characteristics ◊	Total ◊
Patients, number ◊	101 ◊
Microbes (<u>mold</u> , humid hay, cotton) ◊	50 (49.5) ◊
Chemical (insecticides, cement, dye, fertilizers) ◊	18 (17.8) ◊
Animal protein (birds' feather) ◊	8 (7.9) ◊
Enzymes (mushrooms) ◊	1 (1.0) ◊
Metal (fumes) ◊	1 (1.0) ◊
Pharmaceutical agents (drugs) ◊	1 (1.0) ◊
Plant proteins (flour, vegetable processing) ◊	7 (6.9) ◊
Unidentifiable antigen ◊	15 (14.9) ◊

- AMC fibrotic HP cohort (n=101)

HP: online repository of potential cause

hpLung

EXPOSURES

ANTIGENS

ABOUT

Browsing Exposures

Go

	Cases
A	
Air Conditioners	48
Argan Cake	2
B	
Bagasse	16
Baker's Yeast	1
Bathtubs	2
Bats	1
Bed Cleaner	1
Birds, Mixed or NOS	181
Blackbirds	8
Blacksmiths	1
Broom Grass	1
Budgerigars	103

Birds, Mixed or NOS

Also described as bird fancier's lung, bird fancier's disease

There are **181 cases** described in **29 citations**

Citation	Antigens	Cases
2019 Moosaic attenuation Marchiori, E., et al. <i>Jornal Brasileiro De Pneumologia: Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisiologia.</i>		1
2018 [A Case of Acute Exacerbation of Chronic Birdrelated Hypersensitivity Pneumonitis with a Remarkable Elevation of Environmental Avian Antigen Levels] Suzuki, T., et al. <i>Arerugi.</i>	Pigeon Droppings	1
2015 Hypersensitivity pneumonitis associated to birds care González-Zúñiga, A. M., et al. <i>Revista Facultad de Medicina.</i>		1
2015 Identical Twins, Matching Symptoms: Hypersensitivity Pneumonitis Chen, C., et al. <i>American Journal of Medicine.</i>		2
2015 Pneumomediastinum: a rare manifestation of hypersensitivity pneumonitis in a patient presenting with unexplained breathlessness at the Borders General Hospital Grecian, R., et al. <i>BMJ Case Reports.</i>	Avian antigens	1
2015 [Chronic form of bird breeder's disease: about one observation] Frikha, F., et al. <i>The Pan African Medical Journal.</i>		1
2014 [Hypersensitivity pneumonitis in the school environment] Callero, A., et al. <i>Anales De Pediatria.</i>	Aspergillus spp., Canary droppings	1
2013 Bird fancier's lung complicated by pulmonary nocardiosis Komiya, K., et al. <i>Jornal Brasileiro De Pneumologia.</i>		1

Drug-induced interstitial lung disease

Antibiotics

Nitrofurantoin, acute and chronic
Sulfasalazine

Anti-inflammatory agents

Aspirin
Gold
Pencillamine

Chemotherapeutic agents

Antibiotics
Bleomycin sulfate
Mitomycin C
Alkylating agents
Busulfan
Cyclophosphamide
Chlorambucil
Melphalan
Antimetabolites
Azathioprine
Cytosine arabinoside
Methotrexate

Miscellaneous

O₂
Drugs inducing pulmonary infiltrates
and eosinophilia
Radiation
L-tryptophan

Drug-induced systemic lupus erythematosus

Procainamide hydrochloride
Isoniazid
Hydralazine hydrochloride
The hydantoins
Pencillamine

Illicit drugs

Heroin
Methadone hydrochloride
Propoxyphene hydrochloride (Darvon)
Talc

Drug-ILD: online repository of potential cause

PNEUMOTOX ON LINE v2.2
Philippe Camus, M.D.
Dijon, France

Browse by: **DRUGS** PATTERNS

List All | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

- 5-alpha reductase inhibitors** (V1a) ★1
- AZD9291** (I.a, I.b) ★1
- Abacavir** (I.a, I.f, II.a, II.b, IV.d, X.a, X.f, XV.d) ★2
- Abatacept** (I.a, II.b, X.e) ★2
- Abciximab** (III.a, V.n, X.f) ★3
- Abemaciclib** (I.a, I.b, I.c, II.b) ★1
- Abiraterone** (I.a, I.b, II.d, X.r, XII.a, XII.ai) ★2
- Abused drugs/substances (illicit, street drugs - IV/inhaled)** (I.e, I.j, I.m, I.s, I.t, II.b, III.a, IV.a, IV.f, IV.g, V.f, V.q, V.ab, V.b, V.c, V.g, V.i, V.j, V.r, V.t, V.h, V.i, V.ii, V.iii, V.iii.c, V.iii.d, V.iii.ai, IX.a, IX.s, IX.ah, X.m, X.u, X.ac, X.bb, X.l.b, X.l.g, X.l.m, X.l.r, X.ii.g, X.ii, X.ii.y, X.v.q, X.v.s, X.v.v, X.v.sg, X.v.ai, X.vi.u, X.vi.v, X.vi.ab, X.vi.ae, X.vi.af, X.vi.a, X.vii.b, X.vii.g, X.vii.p, X.vii.s, X.vii.u, X.vii.ai, X.viii.t, X.viii.l) ★5

SEARCH
Search by keyword
Advanced search
Identify causative drugs
DIAGNOSING DIRD
FREQUENCY
ALL PATTERNS

LATEST NEWS
Wed, 26 Jan 2022 16:43:22
[Pneumotox revival!](#)
Thu, 11 Mar 2021 14:27:34
[Attention required: users of Pneumotox or Cardiotox APPs](#)
Sun, 04 Oct 2020 15:02:26
[New drugs and the famous nerve agent Novichok](#)
Sat, 07 Mar 2020 22:18:44
[Pneumotox metrics](#)
Fri, 10 Jan 2020 08:11:19
[Attention requested: New AEs from immune checkpoint inhibitors](#)

PNEUMOTOX ON LINE v2.2
Philippe Camus, M.D.
Dijon, France

Browse by: **DRUGS** PATTERNS

Abatacept (★2)
Last update: 09/12/2015

I - Interstitial/parenchymal lung disease

- I.a** **Pneumonitis (ILD), severe (w/wo the features of ARDS)** ★1
- II - Pulmonary edema - Acute lung injury - ARDS**
- II.b** **ARDS - Acute lung injury** ★1
- X - Systemic/Distant conditions, syndromes and reactions**
- X.e** **Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCA, other auto-Abs)** ★1

SEARCH
Search by keyword
Advanced search
Identify causative drugs
DIAGNOSING DIRD

Powered by **MOBILE HEALTH**

ABOUT | COOKIES | CONTACT

ACCP: ILD patient questionnaire

15. Have you lived or worked in environment where you were exposed to heavy smoke or dust? Yes No

16. Occupational history: Please include all occupations in your life.

Occupation	Years worked	Exposures (Dust, metal, paint, fine particles, etc)
_____	_____	_____
_____	_____	_____
_____	_____	_____



17. Have you ever performed any of the following occupations?

- | | | |
|---------------------------------------|--|--|
| <input type="checkbox"/> Farm work | <input type="checkbox"/> Automotive mechanic | <input type="checkbox"/> Carpenter |
| <input type="checkbox"/> Painter | <input type="checkbox"/> Welder | <input type="checkbox"/> Laboratory worker |
| <input type="checkbox"/> Sand blaster | <input type="checkbox"/> Insulator | <input type="checkbox"/> Longshoreman |
| <input type="checkbox"/> Pipe fitter | <input type="checkbox"/> Vineyard worker | |

18. Have you ever worked in any of the following locations?

- | | | |
|------------------------------------|-------------------------------------|--|
| <input type="checkbox"/> Mine | <input type="checkbox"/> Foundry | <input type="checkbox"/> Plastic factory |
| <input type="checkbox"/> Quarry | <input type="checkbox"/> Railroad | <input type="checkbox"/> Tunnel construction |
| <input type="checkbox"/> Pulp mill | <input type="checkbox"/> Paper mill | |
| <input type="checkbox"/> Bakery | <input type="checkbox"/> Smelting | |



19. Have you ever been exposed to the following at work/ home/ elsewhere?

- | Animals and farming | Metals/rocks | Food/ plant Production | Miscellaneous | Skilled |
|--------------------------------------|-------------------------------------|--------------------------------------|--|--|
| <input type="checkbox"/> Birds | <input type="checkbox"/> Beryllium | <input type="checkbox"/> Cheese | <input type="checkbox"/> Cotton | <input type="checkbox"/> Cork |
| <input type="checkbox"/> Feathers | <input type="checkbox"/> Cobalt | <input type="checkbox"/> Maple Bark | <input type="checkbox"/> Wood | <input type="checkbox"/> Detergent (isocyanates) |
| <input type="checkbox"/> Fishmeal | <input type="checkbox"/> Tin | <input type="checkbox"/> Wheat | <input type="checkbox"/> Industrial strength cleaning solution | <input type="checkbox"/> Pottery |
| <input type="checkbox"/> Insecticide | <input type="checkbox"/> Iron oxide | <input type="checkbox"/> Coffee/ tea | <input type="checkbox"/> Oily Nosedrops | <input type="checkbox"/> Talc |
| <input type="checkbox"/> Fertilizer | <input type="checkbox"/> Aluminum | <input type="checkbox"/> Mushroom | | <input type="checkbox"/> Paint |
| | <input type="checkbox"/> Mica | <input type="checkbox"/> Oil | | <input type="checkbox"/> Cement |
| | <input type="checkbox"/> Silica | <input type="checkbox"/> Sugar cane | | <input type="checkbox"/> Pipes |
| | <input type="checkbox"/> Asbestos | <input type="checkbox"/> Malt | | <input type="checkbox"/> Brakes |
| | <input type="checkbox"/> Coal | <input type="checkbox"/> Meat | | <input type="checkbox"/> Tile (ceramic) |

16. 다음 직업 중 종사한 적이 있는 직업이 있으시면 표시해주세요.

- | | | |
|-----------------------------|-------------------------|---------------------------|
| 농부 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 도장공(페인트칠) | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 샌드블라스터(모래분사기)작업 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 배관공 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 자동차 정비 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 용접공 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 절연(전기 통하지 않도록) / 단열 / 방음 처리 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 과수원 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 목수 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 실험실 업무 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 부두 노동자 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |

17. 다음 장소에서 근무한 적이 있으십니까?

- | | | |
|-------------|-------------------------|---------------------------|
| 광산 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 주조(주물)공장 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 제련(용광로)공장 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 채석장 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 철로 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 플라스틱 제조 공장 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 펄프 제작소 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 제지 공장 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 터널 건설 현장 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 제과점(제과 제빵업) | <input type="radio"/> 네 | <input type="radio"/> 아니오 |

18. 집 / 작업장 등에서 다음에 노출된 적이 있으시면 표시해주세요.

- | | | | | | |
|-------------------|-------------------------|---------------------------|-----|-------------------------|---------------------------|
| 동물 / 농업 관련 | | | | | |
| 새 | <input type="radio"/> 네 | <input type="radio"/> 아니오 | 깃털 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 어분(말린 생선가루) | <input type="radio"/> 네 | <input type="radio"/> 아니오 | 살충제 | <input type="radio"/> 네 | <input type="radio"/> 아니오 |
| 비료 | <input type="radio"/> 네 | <input type="radio"/> 아니오 | | | |

ILD is the most common pulmonary manifestation in Autoimmune disease

	SSc	RA	Sjögren's	MCTD	PM/DM	SLE
Airways	-	++	++	+	-	+
ILD	+++	++	++	++	+++	+
Pleural	-	++	+	+	-	+++
Vascular	+++	+	+	++	+	+
DAH	-	-	-	-	-	++

Raynaud's phenomenon



Puffy fingers in early scleroderma or mixed CTD



Advanced sclerodactyly



Gottron's papules in dermatomyositis




Mechanic's hands in anti-synthetase syndrome



Serological evaluation

- Minimum: CRP, ESR, ANA, RF, anti-CCP, *myositis panel*
- Based on history & physical exam, consider:
 - Enzyme (CK, aldolase, myoglobin)
 - Antisynthetase antibodies (Jo-1 and others if available)
 - Anti-MDA5, anti-Mi-2, anti-NXP2, anti-TIF1-r, anti-SRP, anti-HMGCR, anti-SAE, anti-U1RNP, anti-PM/Scl75, anti-PM/Scl100, anti-Ku
 - SSc (suspected): anti-Scl-70/topoisomerase-1, anti-centromere, anti-RNA polymerase III, anti-U1RNP, anti-Th/To, anti-PMscl, U3 RNP, anti-Ku
 - SjS: anti-SSA/Ro, anti-SSB/La
 - Vasculitis: anti-cytoplasmic antibodies


Fine crackles on chest auscultation in the diagnosis of ILD



	None	Fine crackles
IPF n (%)	2 (1.6%)	97 (75.2%)
Non-IPF n (%)	25 (15.5%)	98 (60.9%)
CTD-related ILD	5 (9.8%)	34 (66.7%)
HP	6 (15.8%)	25 (65.8%)
NSIP	1 (5.0%)	14 (70.0%)
Others	13 (24.5%)	25 (47.2%)
Drug-related ILD	3 (25.0%)	6 (50.0%)
Non-specific PF	2 (18.2%)	6 (54.5%)
Unclassifiable ILD	1 (9.1%)	5 (45.5%)
Smoking-related ILD	4 (50%)	2 (25.0%)
Other	3 (30.0%)	6 (60.0%)

Clubbing in patients with fibrotic IP

Schamroth sign test



	Digital index	Phalangeal depth ratio		Schamroth sign	At sight	
N (%)	≥ 10.2	Left	Right	Positive	Physician	Investigator
Total group	10 (7)	50 (33)	47 (31)	12 (8)	63 (41)	64 (42)
IPF	5 (7)	21 (31)	19 (28)	6 (9)	35 (52)	27 (40)
Others	5 (6)	29 (34)	28 (33)	6 (7)	28 (33)	37 (44)
Underlying CVD	1 (5)	3 (16)	3 (16)	2 (11)	7 (37)	8 (42)
CHP	0 (0)	6 (50)	5 (42)	1 (8)	5 (42)	6 (50)
Fibrosing pulmonary sarcoïdose	0 (0)	4 (27)	3 (20)	0 (0)	3 (20)	5 (33)
Unclassifiable PF	0 (0)	6 (35)	7 (41)	1 (6)	6 (35)	8 (47)
Various fibrotic ILDs	4 (18)	10 (46)	10 (46)	2 (9)	7 (32)	10 (46)

Pulmonary function test



- Spirometry
 - Reduced FVC (and TLC)
 - Normal or increased FEV₁/FVC ratio
- Restriction often accompanied by some obstruction
- Impaired gas exchange
 - Decreased DL_{CO}, PaO₂
 - Increased A-aPO₂ gradient
 - Disproportionately reduced: Emphysema, Pulmonary HTN
- Normal PFTs (FVC) do not exclude ILD
 - Emphysema + Interstitial Lung Disease

6MWT in ILD: prognostic value of desaturation


• IPF

• iNSIP


진료구분	외래			진료기간
상병명				투약내용
Pulse	TEST(I) O2		LPM	TIME
	SaO ₂	DISTANCE	RPE	
96	94			resting
				test
100	94			30"
103	86			1'
103	82			1'30"
102	81			2'
97	85			2'30"
98	86			3'
101	88			3'30"
100	91			4'
100	91			4'30"
101	89			5'
102	90			5'30"
102	87	203	5	6'



What are the features of an HRCT?




High Resolution Computed Tomography




- HRCT help to detect more detailed parenchymal changes in ILD.

HRCT: inspiration vs. expiration images

Inspiration




Expiration



- Expiratory image help to detect air-trapping seen in HP or BO.


HRCT: supine vs. prone images



- Prone image help to differentiate GGO/CON from pseudolesion.

UIP pattern


Basal and subpleural predominance



Reticular opacities

Honeycombing

Traction
bronchiectasis





Honeycombing

Traction
bronchiectasis


Probable UIP pattern

Basal and subpleural predominance



- No honeycombing; level of confidence for UIP histology (70-89%); IPF diagnosis without biopsy is possible after MDD in the appropriate clinical setting (eg. 60 yr old, male, smoker)


Bronchoalveolar lavage



Description	결과값	단위
Others fluid Color	Colorless	
Turbidity	Mild turbid	
Specific gravity	1.020	
RBC	20	mm ³
WBC	400	mm ³
Lymphocyte	79	%
Alveolar macrophage	21	%
pH - Other Fluid	5.0	
Description	결과값	단위
T-cell %	94.6	%
T helper/inducer cell %	84.4	%
T helper/inducer cell No	-	/uL
T suppressor/cytotoxic %	6.5	%
T suppressor/cytotoxic No	-	/uL


- Patients with ILD who do not have a UIP pattern on HRCT
- Usefulness:
 - Eosinophilic pneumonia (>25% Eo),
 - Lymph (>20%): sarcoidosis, HP, NSIP
 - Others: PAP, Lipoid Pn, DAH, Smoking-IP, drug-IP, PLCH, infection, malignancy

Bronchial biopsy



	Endobronchial biopsies	Forceps transbronchial biopsies
Very useful	Sarcoidosis Lymphangitic carcinomatosis	Sarcoidosis Lymphangitic carcinomatosis Berylliosis Organising pneumonia Bronchiolo-alveolar carcinoma
Often or occasionally useful	Granulomatosis with polyangiitis Some infections	Diffuse alveolar damage ✓ Alveolar lipoproteinosis Eosinophilic pneumonia ✓ Lymphangioleiomyomatosis ✓ Pulmonary Langerhans cell histiocytosis Silicosis Diffuse lymphoma Some infections Amyloidosis ✓ Hypersensitivity pneumonitis

Video-Assisted Thoracic Surgery (VATS)



- High diagnostic accuracy (~90%)
- Is it safe ? : ~1.7% for elective procedures
- Ideal biopsy
 - Preoperative targeting
 - **Two or more** surgical wedge biopsies **with areas of normal lung** taken from **different areas** of the lung
 - Samples should measure 3–5 cm in length and 2–3 cm in depth

VATS: main contraindications

Age (physiologic) > 75 years

Rapid worsening or acute exacerbation (non-elective biopsy)

Low pulmonary reserve (FVC < 60–70%, DLco < 35–40% of predicted)



Supplementary oxygen at rest

Pulmonary hypertension



Major comorbidities

Immunodepression

Cryobiopsy




- Diagnostic yield in ILD: 79%
- Conditional recommendation in experienced centers



UIP is the histologic hallmarks of IPF


- Spatial and temporal heterogeneity



UIP vs. other fibrosing ILD


- fNSIP

Diffuse and Uniform



- fHP

Airway-centered fibrosis



Histopathologic diagnosis in ILD

An Ailing Gold Standard

Using histology alone as the “gold standard” for diagnosis can be complicated by difficulties with..

1. interrater agreement (*low kappa value*)
2. the potential for sampling error (*intra-patient heterogeneity*)
3. The combination of HRCT and histologic features better predicts prognosis compared with either.

Histopathologic diagnosis in ILD


- Agreement between pathologists

Histologic diagnosis	Lobar diagnosis (n = 98)*	Final diagnosis (n = 48)*
Usual interstitial pneumonia	0.40 (Moderate)	0.49 (Moderate)
Nonspecific interstitial pneumonia	0.32	0.32
Organizing pneumonia	0.59	0.67
Hypersensitivity pneumonitis	0.39	0.35
Sarcoidosis	0.76	0.82
Overall	0.39 (Fair)	0.43 (Moderate)

*kappa coefficients



ILD diagnostic team

Multidisciplinary Discussion



The current gold standard for the diagnosis of IIP is a **dynamic integrated process** that requires **direct interaction between** clinicians and radiologists as well as pathologists.

Multidisciplinary approach improve diagnostic agreement and confidence



- More information and multidisciplinary interactions improve diagnostic agreement and confidence.

Cases in which initial and final pathologic interpretation changed


Thomas V. Colby,

William D. Travis,


Initial Diagnosis	Final Diagnosis
Hypersensitivity pneumonitis	NSIP*
Organizing pneumonia	NSIP
UIP	ILD associated with CVID
Bronchiolar disease	Pulmonary veno-occlusive disease
End-stage lung	IPF
End-stage lung	IPF
End-stage lung	IPF
UIP	NSIP*
UIP	NSIP
Bronchiolar disease	RBILD
Bronchiolar disease	RBILD

- Diagnosis of **19% (11/58)** was changed after C-R-P discussion.

Diagnosis of fibrosing-ILD that may present a progressive phenotype



Proportion of Progressive Pulmonary Fibrosis




ATS/ERS/JRS/ALAT guideline: PPF

Definition of PPF

In a patient with ILD of known or unknown etiology other than IPF who has radiological evidence of pulmonary fibrosis, PPF is defined as at least two of the following three criteria occurring within the past year with no alternative explanation*:

- 1 Worsening respiratory symptoms
- 2 Physiological evidence of disease progression (either of the following):
 - a. Absolute decline in FVC $\geq 5\%$ predicted within 1 yr of follow-up
 - b. Absolute decline in DL_{CO} (corrected for Hb) $\geq 10\%$ predicted within 1 yr of follow-up
- 3 Radiological evidence of disease progression (one or more of the following):
 - a. Increased extent or severity of traction bronchiectasis and bronchiolectasis
 - b. New ground-glass opacity with traction bronchiectasis
 - c. New fine reticulation
 - d. Increased extent or increased coarseness of reticular abnormality
 - e. New or increased honeycombing
 - f. Increased lobar volume loss

Adjusted annual rate of decline in FVC (mL/year) over 52 weeks



Summary

- Clinical approach in ILD diagnosis
 - How thoroughly the patient's history and possible exposures are assessed, determine the possibility of an accurate diagnosis.
 - HRCT is the key of initial diagnostic approach.
 - MDD is the gold standard in diagnosing ILD.
 - Monitoring is important for early detection of PPF.